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Allergic disease is endemic in developed nations, 
and none is more dramatic or deadly than sys-
temic  anaphylactic  shock  (Finkelman,  2007). 
Unfortunately, this collection of rapid changes 
to the cutaneous, vasculature, and pulmonary 
systems  may  also  be  the  least  understood  of 
atopic diseases. A better understanding of the 
eliciting factors for systemic anaphylaxis is there-
fore critical for accurate diagnosis and therapeu-
tic  intervention.  Mast  cells,  which  reside  in 
vascularized tissues and are strategically located 
at the interfaces of host and environment in skin 
and mucosal surfaces, are key effectors of IgE- 
  mediated allergic disorders, including anaphy-
laxis, hay fever, eczema, and asthma. Mast cells 
express FcRI (high-affinity receptors for IgE), 
which binds antigen (Ag)-specific IgE antibod-
ies,  and  subsequent  exposure  to  Ag  initiates 
cross-linking  and  aggregation  of  FcRI.  This 
cascade of events triggers mast cell activation 
and secretion of a wide array of inflammatory 
mediators,  such  as  histamine  and  other  pre-
formed  mediators,  bioactive  lipids,  including 
eicosanoids and platelet-activating factor (PAF), 
and numerous proinflammatory cytokines and 
chemokines (Kalesnikoff and Galli, 2008), which 
are essential to the pathogenesis of allergic   
diseases and anaphylaxis (Finkelman, 2007).
A recent addition to the recognized reper-
toire of lipid mediators secreted by mast cells   
is the sphingolipid metabolite sphingosine- 
1–phosphate (S1P; Jolly et al., 2004; Mitra et al., 
2006; Olivera et al., 2006), which has been im-
plicated in initiation and maintenance of diverse 
aspects of immune cell activation and function 
(Rosen et al., 2008; for review see Schwab and 
Cyster, 2007; Rivera et al., 2008). Focus on 
S1P in immune responses has increased after the 
elucidation  of  its  critical  role  in  lymphocyte 
trafficking (Rosen et al., 2008; for review see 
Schwab and Cyster, 2007), and observations of 
local increases of S1P in inflammatory disorders 
such as asthma (Ammit et al., 2001) and rheu-
matoid arthritis (Kitano et al., 2006). S1P is a li-
gand  for  five  G  protein–coupled  receptors, 
designated  S1P1-5,  through  which  it  exerts 
many of its actions (Spiegel and Milstien, 2003). 
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Systemic exacerbation of allergic responses, in which mast cells play a critical role, results 
in life-threatening anaphylactic shock. Sphingosine-1–phosphate (S1P), a ligand for a 
family of G protein–coupled receptors, is a new addition to the repertoire of bioactive 
lipids secreted by activated mast cells. Yet little is known of its role in human mast cell 
functions and in anaphylaxis. We show that S1P2 receptors play a critical role in regulating 
human mast cell functions, including degranulation and cytokine and chemokine release. 
Immunoglobulin E–triggered anaphylactic responses, including elevation of circulating 
histamine and associated pulmonary edema in mice, were significantly attenuated by the 
S1P2 antagonist JTE-013 and in S1P2-deficient mice, in contrast to anaphylaxis induced by 
administration of histamine or platelet-activating factor. Hence, S1P and S1P2 on mast 
cells are determinants of systemic anaphylaxis and associated pulmonary edema and might 
be beneficial targets for anaphylaxis attenuation and prophylaxis.
© 2010 Oskeritzian et al.  This article is distributed under the terms of an At-
tribution–Noncommercial–Share Alike–No Mirror Sites license for the first six 
months after the publication date (see http://www.rupress.org/terms). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e466 S1P2 axis in anaphylaxis and pulmonary edema | Oskeritzian et al.
anaphylactic responses in mice deficient in SphK2 were nor-
mal (Olivera et al., 2007). An intriguing finding of this study 
was the association between circulating concentrations of S1P 
and susceptibility to anaphylaxis, suggesting that S1P is a key 
factor that determines anaphylactic responses.
Although much has been learned about the roles of the 
SphKs that produce S1P in mast cell functions and anaphylac-
tic responses, little is known about how S1P executes these 
important functions in vivo and which of the S1P receptors is 
involved. To this end, we examined the roles of S1P receptors 
in developing and mature human mast cells and their impor-
tance in IgE-mediated passive systemic anaphylaxis (PSA) in 
mice. Our data provide direct pharmacological, genetic, and 
biological evidence for the importance of S1P and the S1P2 
receptor on mast cells in anaphylaxis and associated pulmo-
nary edema. Hence, S1P and S1P2 may be therapeutic targets 
for clinical intervention in this poorly understood disease.
RESULTS AND DISCUSSION
S1P1 regulates migration of human mast cells toward  
Ag but is not involved in other mast cell functions
Cross-linking of FcRI on mast cells activates SphK1 and 
SphK2, leading to generation and secretion of S1P (Melendez 
Rodent mast cells express S1P1 and S1P2 receptors on their 
cell surface, which function in an autocrine manner to fine-
tune mast cell functions (for review see Olivera, 2008; Price   
et al., 2008). Although S1P1 is important for migration of mast 
cells toward Ag, S1P2 contributes to the robustness of their 
degranulation (Jolly et al., 2004). FcRI engagement on mast 
cells by allergens stimulates sphingosine kinase (SphK) 1 and 
2, the two isoenzymes which produce S1P, and both contrib-
ute to mast cell functions (Jolly et al., 2004, 2005; Urtz et al., 
2004; Olivera et al., 2006, 2007). SphK1, but not SphK2, was 
shown to be important for Ag-induced calcium mobilization, 
degranulation, and migration of human and rodent bone mar-
row–derived mast cells (Melendez and Khaw, 2002; Jolly   
et al., 2004, 2005; Oskeritzian et al., 2008). However, based 
on results with fetal liver–derived mast cells from SphK1 and 
SphK2 knockout mice, it was suggested that SphK2, but not 
SphK1, modulates calcium influx and downstream signaling, 
leading to degranulation and production of eicosanoids and 
cytokines (Olivera et al., 2007). Similarly, SphK2 was also 
necessary for secretion of both TNF and IL-6 by mature hu-
man mast cells (Oskeritzian et al., 2008). Remarkably, how-
ever, mice deficient in SphK1 displayed reduced levels of 
circulating S1P and were resistant to anaphylaxis, whereas 
Figure 1.  S1P1 is not involved in degranulation or cytokine and chemokine secretion from human CB-MCs and Sk-MCs but is essential for 
human mast cell motility. (a–c) Purified CB-MCs were stimulated with vehicle, 100 nM S1P, or 1 µM ionomycin, or sensitized overnight with IgE, and then 
stimulated with 30 ng/ml DNP-HSA (Ag), for 2 h. Where indicated, CB-MCs were pretreated for 30 min with vehicle, 1 µM W146, or 1 µM W140 before 
stimulation. Degranulation was assessed by the percentage of -hexosaminidase release (a). Secretion of CCL2 (b) was measured by ELISA. (c) Duplicate 
cultures pretreated for 30 min with vehicle, 1 µM W146, or 1 µM W140 were allowed to migrate in transwell chambers toward vehicle, 100 nM S1P, 30 ng/
ml Ag, or 20 µg/ml fibronectin (FN) for 24 h. Similar results were obtained in three independent experiments using CB-MC from three different donors.  
(d–h) Sk-MCs were stimulated with vehicle, 100 nM S1P, or 1 µM ionomycin, or sensitized overnight with IgE, and then stimulated with 30 ng/ml Ag for 2 h. 
Where indicated, Sk-MCs were pretreated for 30 min with vehicle or 1 µM VPC23019 before stimulation. Degranulation (d) and secretion of CCL2 (e), IL-6 
(f), and TNF (g) was measured. (h) Migration of duplicate cultures toward vehicle, 100 nM S1P, 30 ng/ml Ag, or 20 µg/ml fibronectin was determined in tran-
swell chambers. Data are expressed as the percentage of migrating cells and are the means ± SD of triplicate determinations. Similar results were obtained 
in three independent experiments using CB-MC and Sk-MC from three different donors. *, P < 0.01, compared with vehicle treatment.JEM VOL. 207, March 15, 2010  467
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induced by S1P and Ag, but not that induced by ionomycin 
(Fig. 3 a), and also reduced CCL2 secretion (Fig. 3 b).
A molecular approach was used to confirm and extend the 
involvement of S1P2 in the activation of human mast cell. To 
this end, S1P2 expression in CB-MC was down-regulated 
with a specific small interfering RNA (siRNA) that efficiently 
inhibited its expression without altering S1P1 (Fig. 3 c). Simi-
lar to the effects of S1P2 antagonism, depletion of the S1P2 re-
ceptor in CB-MC greatly reduced S1P- and Ag-mediated 
degranulation  (Fig.  3  d)  and  CCL2  secretion  (Fig.  3  e), 
whereas activation by ionomycin was not affected (Fig. 3, d 
and e). Moreover, transfection with scrambled siRNA had no 
significant effects. Hence, pharmacological and molecular ap-
proaches demonstrate that the S1P2 receptor, in contrast to 
S1P1, is essential for human mast cell functions, including de-
granulation and cytokine and chemokine release. Although 
the two types of human mast cells, CB-MC and Sk-MC, are 
not functionally identical (Oskeritzian et al., 2005), activation 
of both by cross-linking of FcRI by Ag or by S1P involves 
the S1P2 receptor. Moreover, we previously reported that de-
granulation of bone marrow–derived mast cells derived from 
S1P2 knockout mice was dramatically impaired (Jolly et al., 
2004). Altogether, these results suggest that the S1P–S1P2   
and Khaw, 2002; Urtz et al., 2004; Mitra et al., 2006; Olivera 
et al., 2006, 2007; Oskeritzian et al., 2008). Although these 
kinases that produce S1P have distinct and important roles in 
human mast cells, it is still not well understood how S1P ex-
ecutes these important functions in vivo and which of the 
S1P receptors is involved.
We first examined the role of S1P1, one of the two S1P 
receptors expressed by rodent and human mast cells (Jolly   
et al., 2004; Oskeritzian et al., 2008). In agreement with pre-
vious results (Oskeritzian et al., 2008), S1P potently induced 
degranulation of cord blood-derived mast cells (CB-MCs) to 
almost the same extent as Ag (Fig. 1 a) and also induced sig-
nificant secretion of the chemokine CCL2 (Fig. 1 b), which is 
also known as monocyte chemoattractant protein (MCP) 1. 
However, pretreatment with W146, the preferred R enantio-
mer of a chiral S1P1 selective competitive antagonist (Sanna   
et al., 2006), did not affect either degranulation (Fig. 1 a) or 
secretion of CCL2 induced by S1P, Ag, or ionomycin (Fig. 1 b). 
In contrast, W146 ablated migration of CB-MC toward   
S1P and Ag without affecting migration toward fibronectin 
(Fig. 1 c). This was a specific effect of S1P1 antagonism, as   
the inactive S enantiomer (W140) had no significant effects 
(Fig. 1, a–c). S1P also significantly stimulated degranulation of 
skin-derived mast cells (Sk-MCs) nearly as effectively as Ag 
and triggered secretion of CCL2 and the cytokines IL-6 and 
TNF. Moreover, the S1P1 antagonist VPC23019 had no signif-
icant effects on S1P- or Ag-stimulated degranulation (Fig. 1 d) 
or CCL2 (Fig. 1 e) and cytokine release (Fig. 1, f and g), yet 
it  eliminated  migration  of  Sk-MC  toward  S1P  and  Ag 
(Fig. 1 h). Similarly, the S1P1 antagonist W146 also had no 
significant effects on secretory or excretory responses but pre-
vented migratory responses of Sk-MC to S1P and Ag (Fig. S1).
As cross-linking of FcRI on human mast cell induces 
production and secretion of S1P (Mitra et al., 2006), our 
finding that S1P alone potently induces degranulation and 
cytokine secretion from CB-MC and Sk-MC suggests that 
S1P acts in a positive-feedback loop to amplify and enhance 
mast cell–mediated inflammatory responses in a manner that 
could be destabilizing if not properly controlled. The obser-
vation that the S1P1 receptor regulates migration of human 
mast cell toward Ag, together with other studies demonstrat-
ing a role for S1P1 in trafficking of innate and adaptive im-
mune cells (for review see Schwab and Cyster, 2007; Rivera 
et al., 2008), implies that this receptor may be involved in di-
recting effector cells to sites of allergic inflammation.
S1P2 is pivotal in immunological activation of human mast cells
To examine the role of S1P2, the other S1P receptor present 
on mast cells, we used the selective S1P2 receptor antagonist 
JTE-013, which greatly suppressed degranulation of Sk-MC 
induced by S1P and Ag (Fig. 2 a) and also significantly reduced 
secretion of CCL2 (Fig. 2 b), IL-6 (Fig. 2 c), and TNF (Fig. 2 d). 
These effects of JTE-013 appeared to be specific, as it did not 
alter degranulation or chemokine/cytokine secretion induced 
by the calcium ionophore ionomycin (Fig. 2). Similarly, in 
CB-MC, JTE-013 also markedly suppressed degranulation   
Figure 2.  S1P2 antagonism impairs degranulation and cytokine 
and chemokine secretion from human Sk-MCs. Sk-MCs were stimu-
lated with vehicle, 100 nM S1P, or 1 µM ionomycin, or sensitized over-
night with IgE, and then stimulated with 30 ng/ml Ag for 2 h. Sk-MCs 
were pretreated for 30 min with vehicle or 1 µM JTE013 before stimula-
tion, as indicated. Degranulation was assessed by -hexosaminidase re-
lease (a). Secretion of CCL2 (b), IL-6 (c), and TNF (d) was measured by 
ELISA. Data are the means ± SD of triplicate determinations. Similar re-
sults were obtained in three independent experiments using Sk-MC from 
three different donors. *, P < 0.01, compared with vehicle treatment.468 S1P2 axis in anaphylaxis and pulmonary edema | Oskeritzian et al.
declined thereafter, and approached baseline as the animals re-
covered (Fig. 4 d). Administration of JTE-013 greatly dimin-
ished histamine levels at all time points (Fig. 4, b and d). In 
contrast to histamine, serum levels of the chemokine MCP-
1/CCL2 remained elevated for a longer period of time after 
Ag challenge (Fig. 4 e). JTE-013 also reduced IgE-mediated 
production of both MCP-1/CCL2 (Fig. 4, c and e) and mac-
rophage inhibitory protein (MIP) 1–/CCL3 (Fig. 4 f), im-
portant modulators of monocyte and eosinophil recruitment 
which have previously been shown to increase after in vitro 
treatment of mouse mast cell with S1P (Jolly et al., 2004).
Histamine, chiefly among other mediators secreted by ac-
tivated mast cells, causes the signs of anaphylaxis predominantly 
by promoting vasodilatation and increasing vascular permea-
bility  (Finkelman,  2007).  Accordingly,  IgE-dependent  ana-
phylaxis was associated with extensive lung perivascular edema 
(Fig. 4 h), which is indicative of increased vascular permeabil-
ity, compared with the lungs of mice not challenged with Ag 
(Fig. 4 g). JTE-013 treatment dramatically reduced perivascu-
lar edema (Fig. 4 i), which is consistent with the attenuation of 
mast cell activation by this S1P2 antagonist (Figs. 2 and 3). Al-
together, these results demonstrate that in vivo manifestations 
of Ag-induced anaphylaxis can be attenuated by preventing 
interaction of the mast cell S1P2 receptor with its ligand S1P.
receptor axis is an intrinsic regulator of mast cell responsiveness. 
Furthermore, the clear separation of responsibilities for S1P1 
and S1P2 receptors in mast cell activation allows for indepen-
dent control of migration and inflammatory mediator release.
S1P2 antagonism decreases the severity of PSA
As it appears that S1P2 plays universal roles in activation of 
both rodent and human mast cell, it was of interest to evaluate 
the contribution of the S1P2 receptor to allergic reactions in 
an established mouse model in which mast cells play a promi-
nent role. To this end, we used PSA (Finkelman, 2007), a 
mast cell–dependent model that circumvents the variables of 
Ag sensitization and IgE production. Passive immunization of 
mice with mouse IgE targeted against DNP, followed by i.p. 
injection of the Ag (DNP–human serum albumin [HSA]), 
caused profound systemic anaphylaxis, as judged by a drastic 
drop in core body temperature at 30 min that slowly recov-
ered thereafter (Fig. 4 a). Pretreatment of mice with the S1P2 
antagonist JTE-013 markedly attenuated the severe hypother-
mia induced during Ag challenge (Fig. 4 a). Elevated levels of 
serum histamine, which are responsible for hypothermia in 
IgE-mediated anaphylactic shock (Makabe-Kobayashi et al., 
2002), were markedly increased within 5 min of Ag chal-
lenge, reached maximum levels by 30 min (Fig. 4 b),   
Figure 3.  S1P2 antagonism or down-regulation of S1P2 decreases S1P- and Ag-induced degranulation and chemokine secretion from  
CB-MCs. (a and b) Purified CB-MCs were stimulated with vehicle, 100 nM S1P, or 1 µM ionomycin, or sensitized overnight with IgE, and then stimulated 
with 30 ng/ml Ag for 2 h. CB-MCs were pretreated for 30 min with vehicle or 1 µM JTE013 before stimulation, as indicated. Degranulation (a) and secre-
tion of CCL2 (b) were measured. *, P ≤ 0.01; #, P ≤ 0.05, compared with vehicle treatment. (c–e) CB-MCs transfected with control siRNA or S1P2 siRNA 
were stimulated with vehicle, 100 nM S1P, or 1 µM ionomycin, or sensitized overnight with IgE, and then stimulated with 30 ng/ml Ag for 2 h. (c) RNA 
was isolated and mRNA levels of S1P1, S1P2, SphK1, SphK2, and GAPDH were determined by quantitative real-time PCR. Degranulation (d) and secretion 
of CCL2 (e) were measured. *, P ≤ 0.01; #, P ≤ 0.05, compared with scrambled siRNA. Data are the means ± SD of triplicate determinations. Similar results 
were obtained in three independent experiments with CB-MC from three different donors.JEM VOL. 207, March 15, 2010  469
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Figure 4.  S1P2 antagonist attenuates PSA. C57BL/6 mice were injected i.p. with IgE anti-DNP mAb. 12 h later, mice were injected i.p. with vehicle 
(DMSO; n = 6) or JTE013 (20 µg/mouse; n = 6) and, 30 min later, systemic anaphylaxis was induced by i.p. injection of DNP-HSA. Body temperature was 
monitored at the indicated times (a). Serum levels of histamine at the indicated times (b) or at 120 min (d), MCP-1/CCL2 at the indicated times (c) or at 
120 min (e), and MIP-1/CCL3 at 120 min (f) were determined by ELISA. Data are the means ± SD. (g–i) Representative micrographs of hematoxylin and 
eosin (H&E)–stained lung tissues from control mice (g), Ag-challenged mice (h), and mice treated with JTE013 before Ag challenge (i). Arrows indicate 
pulmonary vascular edema. Note the extensive vascular edema in vehicle-treated Ag-challenged lung (h) compared with JTE013-treated Ag-challenged 
lung (i). Bars, 100 µm. *, P ≤ 0.01; #, P ≤ 0.05, compared with vehicle treated mice. Similar results were obtained in three independent experiments.470 S1P2 axis in anaphylaxis and pulmonary edema | Oskeritzian et al.
S1P2 deficiency attenuates PSA
To confirm the importance of S1P2 through a genetic ap-
proach, we tested S1P2 knockout mice for their ability to   
undergo PSA. Indeed, the severity of anaphylaxis in S1P2  
deficient  mice  was  significantly  decreased  compared  with 
their wild-type counterparts, as shown by an attenuation of 
the Ag-induced decrease of core body temperature (Fig. 5 a) 
and marked reductions in serum levels of histamine (Fig. 5 b), 
MCP-1/CCL2 (Fig. 5 c), and MIP1-/CCL3 (Fig. 5 d). 
Lung histology also demonstrated increased vascular permea-
bility and perivascular edema in wild-type animals after Ag 
challenge (Fig. 5 e), whereas S1P2-deficient mice showed 
much less edema around the blood vessels (Fig. 5 f).
To quantify pulmonary vascular permeability, mice were 
injected with Evan’s blue dye, as an increase in vascular per-
meability allows the dye to leak from the blood vessels into 
the surrounding tissue. After Ag challenge, wild-type mice 
had much greater extravasation of Evans blue into the lung 
than did S1P2
/ mice (Fig. 5 g). These data confirm the   
decreased vascular permeability and less severe anaphylaxis in 
mice devoid of S1P2.
Anaphylaxis triggered by histamine or PAF is unaltered  
by S1P2 blockade or deficiency
It was important to examine whether the S1P2 receptor on 
mast cells alone, and not on other responsive cell types, is   
Figure 5.  PSA is markedly reduced in S1P2 knockout mice. S1P2/ mice (n = 6) and wild-type mice (n = 6) were injected i.p. with IgE anti-DNP 
mAb, and systemic anaphylaxis was elicited 12 h later by injection of DNP-HSA. Body temperature was monitored at the indicated times (a). Serum levels 
of histamine (b), MCP-1/CCL2 (c), and MIP-1/CCL3 (d) at 120 min were determined by ELISA. Data are means ± SD. (e and f) Representative micrographs 
of H&E-stained lung tissues showing extensive pulmonary perivascular edema in Ag-challenged wild-type mice (e), which was nearly absent around lung 
blood vessels of Ag-challenged S1P2
/ mice (f). Arrows indicate pulmonary vascular edema. Lung vascular permeability was determined by quantifying 
Evans blue extravasation (EBAE; g). Similar results were obtained in three independent experiments. *, P ≤ 0.01; #, P ≤ 0.05, compared with wild-type mice. 
Bars, 100 µm.JEM VOL. 207, March 15, 2010  471
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slightly enhanced the drop in body temperature induced by 
histamine injection. Similarly, sensitivity to PAF-induced ana-
phylaxis was not significantly blunted by JTE-013 treatment 
or by deletion of S1P2 (Fig. 6 d). Moreover, extravasation of 
Evans blue in lung induced by histamine (Fig. 6 c) or PAF 
(Fig. 6 e) was not abrogated by S1P2 blockade or by S1P2  
deficiency, which is in sharp contrast to IgE/Ag-induced ana-
phylaxis and edema in lung tissues (Figs. 4 and 5).
Concluding remarks
Collectively with the observations that S1P is released from 
mast cells after cross-linking of FcRI and that their S1P2  
receptors are critical for degranulation and chemokine and 
cytokine release from activated human (Figs. 2 and 3) and 
critical for induction of mast cell–mediated anaphylaxis. We 
were unable to carry out adoptive transfer experiments using 
mast cell–deficient KitW-sh/W-sh mice on the C57BL/6 back-
ground reconstituted with S1P2-deficient mast cells derived 
from C57BL/6 × 129sv mixed background mice because mi-
nor histocompatibility Ags are not conserved between them, 
precluding  transplantation  experiments  without  rejection. 
Thus, to examine whether the reduced signs of anaphylaxis 
from blockade or deficiency of S1P2 are a result of their effects 
on mast cell functions, mast cell degranulation was bypassed 
by administration of exogenous histamine or PAF, which are 
major mediators of anaphylaxis in mice released by activated 
mast cells (Finkelman, 2007). Interestingly, neither JTE-013 
(Fig. 6 a) nor S1P2 deficiency (Fig. 6 b) reduced, but rather 
Figure 6.  Blockade of S1P2 or S1P2 deficiency does not mitigate anaphylaxis triggered by histamine or PAF. (a) C57BL/6 mice were injected i.v. 
with histamine (3 mg/mouse) together with vehicle (n = 6) or JTE-013 (20 µg/mouse; n = 6), and body temperature was monitored at the indicated times. 
(b) C57BL/6 × 129sv wild-type (n = 6) and S1P2 knockout mice (n = 9) were injected i.v. with histamine (3 mg/mouse), and body temperature was moni-
tored. (c) Lung vascular permeability was determined by quantifying Evans blue extravasation. (d) C57BL/6 × 129sv wild-type mice were injected i.v. with 
PAF (500 ng/mouse) together with vehicle (n = 9) or JTE-013 (n = 9). S1P2 null mice were injected with PAF (500 ng/mouse; n = 9). Body temperature was 
monitored at the indicated times. (e) Lung vascular permeability was determined by quantifying Evans blue extravasation in C57BL/6 × 129sv wild-type 
mice and in S1P2 null mice injected i.v. with vehicle, PAF, or JTE-013, as indicated. Data are the means ± SD of triplicate determinations. Similar results 
were obtained in two independent experiments.472 S1P2 axis in anaphylaxis and pulmonary edema | Oskeritzian et al.
MATERIALS AND METHODS
Reagents.  JTE-013  was  obtained  from  Tocris  Bioscience.  VPC23019  and   
W-146 (and its inactive S isomer) were purchased from Avanti Polar Lipids, Inc.
Culture of human mast cells. All protocols involving human tissues were 
approved by the human studies Internal Review Board at Virginia Com-
monwealth University (VCU). Surgical skin samples were obtained from the 
Cooperative Human Tissue Network of the National Cancer Institute or 
from the National Disease Research Interchange. Sk-MCs were prepared as 
previously described (Zhao et al., 2005) and were 100% mast cells, as deter-
mined by staining with toluidine blue. Purified stem cell factor (SCF)– 
dependent CB-MCs were prepared and cultured for 8–12 wk of culture in 
the presence of recombinant human SCF (Amgen) alone as previously de-
scribed (Oskeritzian et al., 2008), and >95% stained positively with toluidine 
blue. Human umbilical cord blood samples were provided by the Labor and 
Delivery station at the VCU Health System (Richmond, VA).
siRNA transfection. Expression of S1P2 was down-regulated by transfec-
tion  with  100  nM  of  sequence-specific  siRNAs  (ON-TARGETplus 
SMARTpool siRNA; Thermo Fisher Scientific) in RPMI 1640 using Oli-
gofectamine (Invitrogen).
Quantitative  RT-PCR.  Total  RNA  was  isolated  with  TRIzol  reagent   
(Invitrogen) and was reverse transcribed with the High Capacity cDNA Re-
verse Transcription kit (Applied Biosystems). Quantitative PCR was performed 
with premixed primer-probe sets using the ABI 7800 (Applied Biosystems).
Degranulation. Degranulation of 106 human mast cells was measured by 
assaying -hexosaminidase release as described previously (Oskeritzian et al., 
2008). Degranulation was expressed as a percentage of the total cellular   
-hexosaminidase released into the medium.
Chemotaxis. Chemotaxis was measured in transwells (Costar; Corning) 
with 8-µm pores, as previously described (Oskeritzian et al., 2008).
Measurements of cytokines and chemokines. Human IL-6, TNF, and 
CCL2/MCP-1 were measured by ELISA (Oskeritzian et al., 2008).
Animals. Protocols and studies involving animals were performed in accor-
dance with the VCU Institutional Animal Care and Use Committee guide-
lines. Mice were maintained in a pathogen-free facility at VCU. C57BL/6J 
and C57BL/6J × 129SV mice were obtained from The Jackson Laboratory, 
and S1P2 knockout mice (R. Proia, National Institutes of Health, Bethesda, 
MD) were maintained on mixed C57BL/6, 129/Sv backgrounds.
PSA. All injections were performed i.p. in a final volume of 100 µl per in-
jection. Mice were injected with 75 µg DNP-specific mouse IgE (provided 
by D. Conrad, VCU, Richmond, VA) and, 12 h later, with 100 µg DNP-
albumin  (Sigma-Aldrich)  in  PBS.  Immediately  before  the  Ag  challenge, 
body temperature of each animal was measured using a rectal microprobe 
(Physitemp Instruments) and monitored up to 90 min after Ag challenge. 
Mice were then euthanized, blood was collected by cardiac puncture for se-
rum  analysis,  and  lungs  were  removed  for  histological  examination. 
  Control mice injected with PBS showed no significant change in body tem-
perature (±1°C) and had blood histamine levels near the limit of detection.
Histology. Lung samples were inflated at the time of dissection with 0.5% 
low melting point agarose solution in 10% formalin. Samples were embed-
ded in paraffin, serial sections stained with H&E, and perivascular areas were 
evaluated in 8–12 randomly selected sections for each sample. Investigators 
had no knowledge of the treatment group assignments at the time of analysis. 
For quantification of lung capillary leakage, mice were injected i.v. with a 
solution of Evans blue dye in albumin (20 mg/kg). The dye was allowed to 
circulate for 30 min, mice were killed, and their lungs were flushed with 
PBS containing 5 mM EDTA. Lungs were then weighed and Evans blue 
rodent mast cells (Jolly et al., 2004), our data provide evi-
dence for the importance of S1P and its S1P2 receptor on 
mast cells in mast cell–mediated anaphylactic shock. Loss of 
S1P2 expression in mice or S1P2 blockade with a specific an-
tagonist decreased the anaphylactic responses and lung peri-
vascular edema triggered by Ag challenge. In contrast, direct 
induction of anaphylaxis and lung leakage by injection of the 
mast cell mediators histamine or PAF was independent of 
S1P2 receptor status. Hence, engagement of S1P2 receptors 
on  mast  cells  by  S1P  upon  cross-linking  of  FcRI  with   
IgE/Ag  acts  to  enhance  and  amplify  mast  cells  functions   
(Rivera and Gilfillan, 2006; for review see Price et al., 2008) 
that are important for anaphylaxis in mice. Indeed, interfer-
ing with the S1P–S1P2 receptor axis drastically reduced cir-
culating levels of histamine, whose rapid secretion from mast 
cells results in systemic vasodilation associated with a sudden 
drop in body temperature, increased vascular permeability, 
and edema of bronchial mucosa (Makabe-Kobayashi et al., 
2002; Finkelman, 2007; Galli et al., 2008).
Specifically targeting the S1P2 receptor may have impor-
tant clinical and therapeutic implications for allergic diseases. 
Just as we found divergent roles for S1P1 and S1P2 in mast 
cell functions, there are other opposing physiological and 
pathological roles for these receptors, suggesting that com-
plete S1P blockade may be complicated or even dangerous. 
Previous studies have conclusively demonstrated that S1P, 
via ligation of the S1P1 receptor, enhances endothelial cell 
barrier function in vivo and in vitro (Garcia et al., 2001; 
Paik et al., 2004; McVerry and Garcia, 2005). A recent ele-
gant study provided convincing evidence that plasma S1P 
maintains vascular integrity and prevents lethal responses to 
leak-inducing agents in adult mice by a mechanism that in-
volves activation of S1P1, most likely on endothelial cells 
(Camerer et al., 2009). Conversely, treatment with the S1P1 
antagonist W146 caused pulmonary edema (Sanna et al., 
2006). Thus, although S1P1 elicits inflammatory cell migra-
tion, it also has physiological protective effects on the vascu-
lature  that  dampen  endothelial  permeability.  In  contrast, 
ligation of S1P2 on endothelial cells increases vascular per-
meability (Sanchez et al., 2007). However, it seems unlikely 
that the marked reduction in pulmonary edema after Ag 
challenge by the S1P2 antagonist JTE-013 or depletion of 
S1P2 is the result of an improvement of barrier integrity, as 
neither JTE-013 nor knockout of S1P2 reduced sensitivity 
to histamine or PAF. Thus, activation of mast cell S1P2 and 
endothelial cell S1P1 receptors (Camerer et al., 2009) may 
be critical in determining the extent of anaphylactic shock 
by regulating mast cell functions and vascular permeability, 
respectively. In sum, our data demonstrate the importance 
of S1P and its S1P2 receptor in mast cell activation and ana-
phylaxis and suggest that specific targeting of the S1P–S1P2 
receptor axis could be a novel therapeutic strategy to control 
acute life threatening exacerbations of anaphylactic shock 
and other diseases where systemic mast cell activation has 
been identified as critical for the induction and promotion 
of initial inflammatory events.JEM VOL. 207, March 15, 2010  473
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